Pharmaceutical R&D process (PR&DP) has been deeply
investigated by different streams of literature; the interest is due to the strategic
implication of the related decisions undertaken. The PR&DP has been
revolutionised by the biotech advent and as a consequence R&D managers
cannot avoid to consider Open Innovation paradigm during this decision
process. Starting from a Real Option optimization model available in literature,
the paper aims at proposing a decision support system (DSS) able to suggest
the candidate products to be included in the best R&D portfolio varying input
parameters (resilient products), to provide a products Pareto analysis that aims
at individuating the products for which it is worthwhile to acquire a deeper
input parameters knowledge and to draw what if rules. The proposed DSS has
been applied to a numerical example available in literature and research
findings show interesting managerial and academic implications